Global Blood Plasma Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Blood Plasma Market Research Report 2024
Colloids (blood plasma) are the substances of expanding the circulating blood volume, which mainly contain albumin type, gelatin type, dextran type and hydroxyethyl starch type.
Colloids (Blood Plasma) can be applied for extensive burns, massive blood or plasma loss and hypovolemic shock. In this report, we calculate colloids (blood plasma) preparations, which is produced by albumin, gelatin, dextran and hydroxyethyl starch.
According to Mr Accuracy reports’s new survey, global Blood Plasma market is projected to reach US$ 478.8 million in 2034, increasing from US$ 406.7 million in 2024, with the CAGR of 2.3% during the period of 2023 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Blood Plasma market research.
North America is the largest Colloids (Blood Plasma) market with about 33% market share. Europe is follower, accounting for about 28% market share.
The key players are CSL Behring, Baxter, Grifols, Octapharma, Kedrion, Shanghai Raas, CTBB, Hualan Bio, Rongsheng Pharmaceutical, Boya Rongsheng, B. Braun Medical, Fresenius Kabi, HOSPIRA, Axa parenterals, Fresenius Kabi(China), CR Double-Crane, Kelun Group, Shandong Qidu Pharmaceutical, Shandong Hualu Pharmaceutical, Minsheng Pharma, Kanglepharm etc. Top 3 companies occupied about 46% market share.
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Blood Plasma market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Baxter International
CSL
Grifols
Octapharma
ADMA Biologics
Cerus Corp
Sanquin
Shanghai Raas
TCS Biosciences
Segment by Type
Immunoglobulin
Albumin
Protease Inhibitors
Coagulation Factor Concentrates
Others
Hospitals and Clinics
Research Laboratories
Academic Institutions
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Blood Plasma report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Colloids (Blood Plasma) can be applied for extensive burns, massive blood or plasma loss and hypovolemic shock. In this report, we calculate colloids (blood plasma) preparations, which is produced by albumin, gelatin, dextran and hydroxyethyl starch.
According to Mr Accuracy reports’s new survey, global Blood Plasma market is projected to reach US$ 478.8 million in 2034, increasing from US$ 406.7 million in 2024, with the CAGR of 2.3% during the period of 2023 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Blood Plasma market research.
North America is the largest Colloids (Blood Plasma) market with about 33% market share. Europe is follower, accounting for about 28% market share.
The key players are CSL Behring, Baxter, Grifols, Octapharma, Kedrion, Shanghai Raas, CTBB, Hualan Bio, Rongsheng Pharmaceutical, Boya Rongsheng, B. Braun Medical, Fresenius Kabi, HOSPIRA, Axa parenterals, Fresenius Kabi(China), CR Double-Crane, Kelun Group, Shandong Qidu Pharmaceutical, Shandong Hualu Pharmaceutical, Minsheng Pharma, Kanglepharm etc. Top 3 companies occupied about 46% market share.
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Blood Plasma market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Baxter International
CSL
Grifols
Octapharma
ADMA Biologics
Cerus Corp
Sanquin
Shanghai Raas
TCS Biosciences
Segment by Type
Immunoglobulin
Albumin
Protease Inhibitors
Coagulation Factor Concentrates
Others
Segment by Application
Hospitals and Clinics
Research Laboratories
Academic Institutions
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Blood Plasma report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source